US FDA has granted final approval to Dr Reddy’s to make cheaper copies of Roche Holding AG’s antiviral Valcyte
Dr Reddy's is all set to launch generic version of Valcyte (Valacyclovir Hydrochloride) in the US market soon. (Photo: DC/File)
Hyderabad: Drug maker Dr Reddy’s Laboratories on Friday said that the company is all set to launch generic version of Valcyte (Valacyclovir Hydrochloride) in the US market soon.
Valganciclovir Hydrochloride is prescribed to patients with AIDS for the treatment of cytomegalovirus (CMV) retinitis (When CMV virus infects the eyes, it is called CMV retinitis).
The US FDA has granted final approval to Dr Reddy’s to make cheaper copies of Roche Holding AG’s antiviral Valcyte. The Hyderabad-based drug maker is set to gain with this approval. Following the news, its stock gained 4.51 per cent to settle at Rs 3,400 on the BSE. On the NSE, it jumped 4.40 per cent to close the day at Rs 3,395. Its market cap climbed by Rs 2,476.87 crore to Rs 57,899.87 crore.
( Source : PTI )
Next Story
